Literature DB >> 15262026

Improving the acceptability of the atrial defibrillator for the treatment of persistent atrial fibrillation: the atrial defibrillator sedation assessment study (ADSAS).

Andrew R J Mitchell1, Philip A R Spurrell, Bart E W Gerritse, Neil Sulke.   

Abstract

BACKGROUND: To compare the acceptability and effectiveness of three pre-medication regimens for manually activated cardioversion of recurrent persistent atrial fibrillation.
METHODS: Eighteen patients implanted with the Jewel AF atrial defibrillator for drug-resistant persistent atrial fibrillation only were studied in an open-labelled randomised crossover study. Patients were assigned to sedation (S) with midazolam elixir, analgesia (A) with morphine sulphate or combination therapy (C) with dextromoramide and lorazepam. Pre-medication was taken up to 1 h before cardioversion. Patients rotated through each type of medication after undertaking at least one cardioversion. Visual analogue scales were completed immediately post-cardioversion and 24 h later for pain, anxiety and 'unpleasantness'. Higher scores represented a worse outcome.
RESULTS: After 2 years' follow-up, 238 cardioversions were performed with S, 17 with A and 35 with C. The mean immediate combined score for S (10.9, 95% confidence interval (CI) 8.2-13.6) was significantly lower than for A (17.3, 95% CI 15.1-19.5, P = 0.01) and for C (15.9, 95% CI 12.3-19.6, P = 0.02). All patients who used S chose it as the most favourable pre-medicant. All patients who used A found it the least acceptable.
CONCLUSION: Sedation rather than analgesia enhanced the acceptability of manually activated atrial defibrillation. Copyright 2003 Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15262026     DOI: 10.1016/j.ijcard.2003.04.060

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Low-energy multistage atrial defibrillation therapy terminates atrial fibrillation with less energy than a single shock.

Authors:  Wenwen Li; Ajit H Janardhan; Vadim V Fedorov; Qun Sha; Richard B Schuessler; Igor R Efimov
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-10-06

Review 2.  Internal defibrillation: where we have been and where we should be going?

Authors:  Samuel Lévy
Journal:  J Interv Card Electrophysiol       Date:  2005-08       Impact factor: 1.900

Review 3.  Is An Atrial Defibrillator Still An Option In Treating Patients With Atrial Fibrillation?

Authors:  Ziad El Khoury; Deepak Bhakta
Journal:  J Atr Fibrillation       Date:  2013-02-12

4.  Multistage electrotherapy delivered through chronically-implanted leads terminates atrial fibrillation with lower energy than a single biphasic shock.

Authors:  Ajit H Janardhan; Sarah R Gutbrod; Wenwen Li; Di Lang; Richard B Schuessler; Igor R Efimov
Journal:  J Am Coll Cardiol       Date:  2013-09-26       Impact factor: 24.094

Review 5.  Intracardiac atrial defibrillation.

Authors:  Derek J Dosdall; Raymond E Ideker
Journal:  Heart Rhythm       Date:  2006-12-28       Impact factor: 6.343

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.